Hemab Therapeutics Hldgs (COAG) Stock Price, Quote, News & History | Benzinga

Hemab Therapeutics Holdings Inc (COAG) Stock Price, Quote, News & History

COAGNASDAQ

Trade with Public

Trade with Public

$44.70

0.681.54%

At close: Sep 1, 5:00 PM EST

$44.71

0.691.57%

Pre-Market: 7:00 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

-

Close

$44.70

Volume / Avg.

627.00 / 353.39K

Day Range

- - -

52 Wk Range

23.00 - 55.42

Market Cap

$2.09B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

-

Days to Cover

6.16

Recent Hemab Therapeutics Holdings Inc News

Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

Shares of Webuy Global Ltd (NASDAQ:WBUY) rose sharply in pre-market trading. Webuy reported record preliminary unaudited travel bookings of around $4.76 million during the three-day NATAS Fair in Aug. 2026,

Avi Kapoor

Hemab Advances Bleeding Disorder Pipeline

Hemab reports new HMB-002 Von Willebrand disease data, and introduced HMB-003, targeting heavy menstrual bleeding.

Vandana Singh

This Charles River Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Top Wall Street analysts upgraded MITT & MFA. See ratings & price targets for these stocks. Should you buy MFA?

Avi Kapoor

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts changed outlook on top names. See all changes, including upgrades/downgrades/coverage initiations at Benzinga's analyst ratings page.

Avi Kapoor

This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-77.33M

Investing Cash Flow (TTM)

-220.27M

Financing Cash Flow (TTM)

473.48M

Free Cash Flow (TTM)

-77.47M

Capital Expenditure (TTM)

-135.00K

Net Change in Cash (TTM)

175.88M

Analyst Trends and Forecast

4

May

2

Jun

3

Jul

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.63B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.60

Earnings Yield % (TTM)

-3.98%

Earnings Yield % (FWD)

-6.28%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$9.72

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$107.00K

Total Cash

$237.37M

Debt to Equity

0.00

Issuance of Debt (TTM)

-$107.00K

Repayment of Debt (TTM)

-$107.00K

Key Statistics

Open

-

Close

$44.70

Volume / Avg.

627.00 / 353.39K

Day Range

- - -

52 Wk Range

23.00 - 55.42

Market Cap

$2.09B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

-

Days to Cover

6.16

About

Sector

Health Care

Industry

Biotechnology

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann th...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Hemab Therapeutics Hldgs (COAG) stock?

A

You can purchase shares of Hemab Therapeutics Hldgs (NASDAQ:COAG) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Hemab Therapeutics Hldgs (COAG) competitors?

A

Other companies in Hemab Therapeutics Hldgs’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Hemab Therapeutics Hldgs (COAG) stock?

A

Hemab Therapeutics Hldgs has a consensus price target of $51.40.

Q

What is the current price for Hemab Therapeutics Hldgs (COAG)?

A

The stock price for Hemab Therapeutics Hldgs (NASDAQ: COAG) is $44.71 last updated September 3, 2026 at 4:10 AM EDT.

Q

Does Hemab Therapeutics Hldgs (COAG) pay a dividend?

A

There are no upcoming dividends for Hemab Therapeutics Hldgs.

Q

When is Hemab Therapeutics Hldgs (NASDAQ:COAG) reporting earnings?

A

Hemab Therapeutics Hldgs does not have any upcoming earnings scheduled.

Q

Is Hemab Therapeutics Hldgs (COAG) going to split?

A

There is no upcoming split for Hemab Therapeutics Hldgs.

Q

What sector and industry does Hemab Therapeutics Hldgs (COAG) operate in?

A

Hemab Therapeutics Hldgs is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.